19 Kasım 2026, Perşembe · 18:00 Piyasalar Kapalı
borsapanel.com Borsanın nabzı, tek panelde.
Abone Ol

Why Quanex Stock Skyrocketed by 22% on Friday

Why Quanex Stock Skyrocketed by 22% on Friday

Eric Volkman, The Motley Fool

Sat, September 5, 2026 at 2:34 AM GMT+3 3 min read

Quanex Building Products (NYSE: NX) stock was doing quite a good job of building investor wealth on the final day of the trading week. Thanks to a freshly issued earnings report that featured a crushing earnings beat, investors piled into the stock to leave it with a double-digit Friday gain of over 22%.

Third quarter triumph

Quanex published its fiscal third-quarter earnings release after market close on Thursday. For the period, it booked net sales of $501.8 million, which was up by 1% year over year. Net income not under generally accepted accounting principles (non-GAAP, or adjusted) rose higher, improving by 14% to $36 million, or $0.79 per share.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

Image source: Getty Images.

The company's revenue came in slightly over the consensus analyst estimate of $498.4 million. We can't say the same for adjusted profitability, as Quanex blew well past the $0.65 per share collectively anticipated by those pundits.

In the earnings release, Quanex said its net sales were affected by favorable pricing developments. These, however, were offset by tariff reimbursements to clients. That pricing dynamic boosted profitability, along with other factors such as lower depreciation and amortization, and relatively modest interest payments.

Constructing a winner

Quanex operated in a relatively volatile environment during the quarter, marked by grinding conflict in the Middle East and persistent economic inflation. So it's admirable that it squeezed out some growth, particularly with that double-digit bottom-line gain.

Management's evident ability to navigate challenging times and conditions bodes well for the company, and I'd say this makes its stock worth a look -- particularly for investors bullish on the U.S. construction sector these days.

Should you buy stock in Quanex Building Products right now?

Before you buy stock in Quanex Building Products, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Quanex Building Products wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $445,833!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,402,153!*

That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of September 4, 2026.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why Quanex Stock Skyrocketed by 22% on Friday was originally published by The Motley Fool

Kaynak: Yahoo Finance
İlgili Haberler
Global Whirlpool India MY27 2. Çeyrek sunum slaytları: Gelir %14 arttı, kâr marjları daraldı Investing.com · 8 dk önce Global Vesalius Longevity Labs, Uzun Ömür Girişimcisi Dr. Peter Diamandis'i Yönetim Kuruluna Atadı Investing.com · 8 dk önce Global Micron, Intel ve diğer yapay zekâ hisseleri Perşembe günü neden yükseliyor? MarketWatch Top · 8 dk önce Global Woodward hisseleri bugün neden yükseliyor? Investing.com · 9 dk önce Global Evogene 2026 üçüncü çeyrek sunumları, %75'lik gelir düşüşü yaşanırken yapay zekâ destekli ilaç geliştirme sürecindeki ilerlemeyi vurguluyor Investing.com · 10 dk önce

Yorumlar (0)

Giriş yaparak yorum yazabilirsin.

İlk yorumu sen yaz.